作者
Michela Giustozzi, Giancarlo Agnelli, Jorge del Toro-Cervera, Frederikus A Klok, Rachel P Rosovsky, Anne-Céline Martin, Joerg Herold, Inna Tzoran, Sebastian Szmit, Laurent Bertoletti, Cecilia Becattini, Menno V Huisman
发表日期
2020/5/4
期刊
Thrombosis and Haemostasis
出版商
Georg Thieme Verlag KG
简介
Background International guidelines have endorsed the use of edoxaban or rivaroxaban as an alternative to low-molecular-weight heparin (LMWH) for the treatment of acute venous thromboembolism (VTE) in cancer patients. Recently, a large randomized controlled trial of apixaban versus dalteparin in patients with cancer was completed. We performed an updated meta-analysis to assess the efficacy and safety of direct oral anticoagulants (DOACs) versus LMWH in patients with cancer-associated VTE.
Methods MEDLINE, EMBASE, and CENTRAL (Cochrane Controlled Trials Registry) were systematically searched up to March 30, 2020 for randomized controlled trials comparing DOACs versus LMWH for the treatment of VTE in patients with cancer. The two coprimary outcomes were recurrent VTE and major bleeding at 6 months. Data were pooled by the Mantel–Haenszel method and compared by relative …
学术搜索中的文章
M Giustozzi, G Agnelli, J del Toro-Cervera, FA Klok… - Thrombosis and haemostasis, 2020